Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2–Targeted Agent in the Real-World Setting
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose This study aimed to evaluate the survivals of patients with metastatic or recurrent gastric cancer (MRGC) over a period of 16 years and to investigate the recent changes in chemotherapy patterns. Materials and Methods A total of 5,384 patients who received chemotherapy for MRGC between 2000 and 2015 were analyzed. The analysis focused on a comparison of the first-line chemotherapy between four periods: 2000-2003 (period 1), 2004-2007 (per-iod 2), 2008-2011 (period 3), and 2012-2015 (period 4). Results There were 880 patients (16%) in period 1, 1,573 (29%) in period 2, 1,435 (27%) in period 3, and 1,496 (28%) in period 4. Cytotoxic doublet-based therapy was the most commonly used (78%) first-line chemotherapy, and the combination of trastuzumab and doublet chemotherapy was provided to 288 patients. The overall survival (OS) rates at 12 and 24 months were steadily improved as follows: 39.2% and 14.6% in period 1, 43.5% and 17.6% in period 2, 50.3% and 20.6% in period 3, and 51.7% and 24.1% in period 4, respectively (p < 0.001). Among the patients who received the doublet-based chemotherapy, the median OS of those who received trastuzumab was 18.0 months (95% confidence interval [CI], 15.5 to 20.6), while that of those who received other doublet therapies was 11.2 months (95% CI, 10.8 to 11.6). Conclusion The OS was improved over time with advancements in chemotherapy, particularly the introduction of the anti-HER2–targeted agent, which contributed to the increase in the number of long-term survivors and established the superiority of OS for the treatment of MRGC.
Abstract
Purpose This study aimed to evaluate the survivals of patients with metastatic or recurrent gastric cancer (MRGC) over a period of 16 years and to investigate the recent changes in chemotherapy patterns. Materials and Methods A total of 5,384 patients who received chemotherapy for MRGC between 2000 and 2015 were analyzed. The analysis focused on a comparison of the first-line chemotherapy between four periods: 2000-2003 (period 1), 2004-2007 (per-iod 2), 2008-2011 (period 3), and 2012-2015 (period 4). Results There were 880 patients (16%) in period 1, 1,573 (29%) in period 2, 1,435 (27%) in period 3, and 1,496 (28%) in period 4. Cytotoxic doublet-based therapy was the most commonly used (78%) first-line chemotherapy, and the combination of trastuzumab and doublet chemotherapy was provided to 288 patients. The overall survival (OS) rates at 12 and 24 months were steadily improved as follows: 39.2% and 14.6% in period 1, 43.5% and 17.6% in period 2, 50.3% and 20.6% in period 3, and 51.7% and 24.1% in period 4, respectively (p < 0.001). Among the patients who received the doublet-based chemotherapy, the median OS of those who received trastuzumab was 18.0 months (95% confidence interval [CI], 15.5 to 20.6), while that of those who received other doublet therapies was 11.2 months (95% CI, 10.8 to 11.6). Conclusion The OS was improved over time with advancements in chemotherapy, particularly the introduction of the anti-HER2–targeted agent, which contributed to the increase in the number of long-term survivors and established the superiority of OS for the treatment of MRGC.
참고문헌 (24)
- Van Cutsem E, "Gastric cancer", Lancet, 388, pp.2654~2664 (2016)
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2019", Cancer Research and Treatment, 51(2), pp.431~437 (2019), 대한암학회
- Guideline Committee of the Korean Gastric Cancer Association, "Korean Practice Guideline for Gastric Cancer 2018; Evidence-based, Multi-disciplinary Approach", Journal of Gastric Cancer, 19(1), pp.1~48 (2019), 대한위암학회[DOI]
- Dekker E, "Colorectal cancer", Lancet, 394, pp.1467~1480 (2019)
- Arbour KC, "Systemic therapy for locally advanced and metastatic non-small cell lung cancer : a review", JAMA, 322, pp.764~774 (2019)
- Park YH, "Capecitabine in combination with Oxaliplatin(XELOX)as a first-line therapy for advanced gastric cancer", Cancer Chemother Pharmacol, 61, pp.623~629 (2008)
- Kang YK, "Capecitabine", cisplatin versus 5-fluorouracil, Ann Oncol, pp.2009, 20[DOI]
- Ryu MH, "Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and", or recurrent gastric cancer : a multicenter, randomized phase III trial(SOS), 2015, pp.26, 2097~2101
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Ohtsu A, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a randomized, double-blind, placebo-controlled phase III study", J Clin Oncol, 29, pp.3968~3976 (2011)
- Lordick F, "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND) : a randomised, open-label phase 3 trial", Lancet Oncol, 14, pp.490~499 (2013)
- Tabernero J, "Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer(JACOB) : final analysis of a double-blind, randomised, placebo-controlled phase 3 study", Lancet Oncol, 19, pp.1372~1384 (2018)
- Boku N, "Safety and efficacy of nivolumab in combination with S-1", capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric, Ann Oncol, pp.2019, 30[DOI]
- Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW) : a double-blind, randomised phase 3 trial", Lancet Oncol, 15, pp.1224~1235 (2014)
- Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial", Lancet, 383, pp.31~39 (2014)
- Chau I, "Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer", Gastric Cancer, 23, pp.133~141 (2020)
- Koo DH, "Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer : 12 years of experience at a single institution", Gastric Cancer, 18, pp.346~353 (2015)
- Koo DH, "A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer : validation and comparison with previous models", Cancer Chemother Pharmacol, 68, pp.913~921 (2011)
- Kang JH, "Salvage chemotherapy for pretreated gastric cancer : a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone", J Clin Oncol, 30, pp.1513~1518 (2012)
- Al-Batran SE, "Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma(FLOT4) : a randomised, phase 2", 3 trial, 2019, pp.393, 1948~1957
- Kang YK, "Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)", Ann Oncol, 30(Suppl 5), pp.v8767~ (2019)
- Al-Batran SE, "Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer : the AIO-FLOT3 trial", JAMA Oncol, 3, pp.1237~1244 (2017)
- Thuss-Patience PC, "Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer : a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie(AIO)", Eur J Cancer, 47, pp.2306~2314 (2011)
- Kang YK, "Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 390, pp.2461~2471 (2017)